ARCHIVE
ID Number: FT-20-9415



This research is provided for historical perspective;
portions of this document may not reflect current conditions.






Oracle's Bid for PeopleSoft: Update 2 September
2 September 2003
 
Betsy Burton   Bruce Bond   Jeff Comport   Robert P. Desisto   Lee Geishecker   Simon Hayward   Brian Zrimsek  

With its tender offer for PeopleSoft, Oracle is attempting to gain more control over broader markets. Gartner advises how this offer could affect you.









Browse Topics


Other Options







Contact Gartner






Download Document:

PDF

oracles_bid_for...pdf (41.4KB)

Help with Downloads




News Analysis




Event

As of 2 September 2003, the latest developments in Oracle's unsolicited bid to acquire PeopleSoft include:

  • On 29 August 2003, PeopleSoft announced that it has purchased all remaining shares of J.D. Edwards that were not tendered in its acquisition on 18 July.
  • On 8 August 2003, Oracle extended the deadline for its bid to buy PeopleSoft from 15 August 2003 to 19 September 2003 and reiterated the offer price of $19.50 per share.
  • On 28 July 2003, Oracle said it would delay its legal attack on PeopleSoft's "poison pill" provisions, pending an outcome from the ongoing Department of Justice inquiry. No new trial date has been set, but it will likely start in September 2003.



Analysis

Gartner expects PeopleSoft and Oracle will continue with legal, marketing and financial moves to advance their respective positions. However, until the U.S. Department of Justice rules on its antitrust inquiry into Oracle’s bid for PeopleSoft, the deal is in limbo. We anticipate no developments that will substantially alter the situation before the Justice Department rules. When its inquiry will conclude is unknown, but it could possibly stretch months beyond September 2003.

PeopleSoft will continue business as usual, with joint PeopleSoft and J.D. Edwards teams working on product road maps, which Gartner expects in early September. Oracle will continue to synchronize its moves on the legal and financial fronts as it demonstrated most recently by extending its offer and postponing until September any legal action to remove the obstacle of PeopleSoft's poison pill.

As we indicated during our analysis of the news of the original Oracle bid, we believe that Oracle faces significant hurdles. Among these are the Justice Department ruling, the PeopleSoft poison pill, and the expanded (and staggered term) PeopleSoft board. We see nothing on the immediate horizon to indicate a lessening of these hurdles. Until the Justice Department rules on this case, Gartner continues to advise clients considering PeopleSoft and J.D. Edwards offerings to use Gartner's decision frameworks to determine their strategy. The frameworks yield different advice, depending on each client's view of whether the Oracle deal will be completed and whether product delivery will be disrupted, balanced with the client's risk tolerance (see "Short-Term Advice for PeopleSoft Customers and Prospects" and "Short-Term Advice for J.D. Edwards Clients: Update 18 July"). Clients aiming to sign strategic software agreements with these vendors (and in general) should include best-in-class terms, conditions and policies that protect their software investments, particularly in areas such as support, upgrades, migration and service (see "Contractual Protections for PeopleSoft Customers").

For Further Information and Research

Gartner continues to work on research related to the individual markets affected and the impact on customers of other vendors. We encourage clients to review our current research, and if you have specific questions, talk with your Gartner analyst — by phone (United States +1 203 316 1266, Europe +44 1784 267770) or e-mail (bizapps@gartner.com, euro.inquiry@gartner.com). Gartner offers the following research:









Browse Topics:
 





© 2003 Gartner, Inc. and/or its Affiliates. All Rights Reserved. Reproduction and distribution of this publication in any form without prior written permission is forbidden. The conclusions, projections and recommendations represent Gartner's initial analysis. As a result, our positions are subject to refinements or major changes as Gartner analysts gather more information and perform further analysis. Gartner disclaims all warranties as to the accuracy, completeness or adequacy of such information. Although Gartner's research may discuss legal issues related to the information technology business, Gartner does not provide legal advice or services and its research should not be construed or used as such. Gartner shall have no liability for errors, omissions or inadequacies in the information contained herein or for interpretations thereof. The opinions expressed herein are subject to change without notice.




Resource Id: 408324